Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α

Fig. 1

Frequency of immune cell types in patients with CML receiving TKIs, either alone or in combination with IFN-α, and in healthy controls. a Pie charts summarizing the distribution of T cells, CD4+ and CD8+ major subsets, and NK cells in the blood of CML patients and healthy controls. TCM = central memory T cell; TEM = effector memory T cell; TEMRA = terminally differentiated, effector memory T cell. b Serum IL-21 levels in a subgroup of patients receiving either TKIs alone of TKIs in combination with IFN-α, and in healthy controls. Results were compared with one-way ANOVA with Tukey’s multiple comparisons test

Back to article page